CAMP4 Therapeutics Corporation(CAMP)

Biotechnology · Cambridge, MA

$3.90-0.11 (-2.74%)

Delayed quote: Oct 6, 2026, 10:10 AM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T14:11:13.311Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:11:13.311Z.

Quote observation: 2026-10-06T14:10:09.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -50,561,000
Quote market capitalization: 244,737,480
Total debt · period ending 2026-06-30: 2,372,000
Cash · period ending 2026-06-30: 87,128,000

FMP input reference: 5c882cca81b2c0fe2c09916b57b0a50c93804d18514abf2397940823ad07c5bd

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CAMP EBITDA Yield Metrics

EBITDA YIELD

N/A

CAMP Competitors' EBITDA Yield

CAMP

CAMP4 Therapeutics Corporation

Current

Market Cap

$244.74M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LFCR

Lifecore Biomedical, Inc.

vs CAMP

Market Cap

$243.81M

EBITDA Yield

N/A

TTM Avg

3.52%

3Y Avg

3.58%

5Y Avg

4.02%

GLSI

Greenwich LifeSciences, Inc.

vs CAMP

Market Cap

$243.66M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IFRX

InflaRx N.V.

vs CAMP

Market Cap

$241.56M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HITI

High Tide Inc.

vs CAMP

Market Cap

$240.76M

EBITDA Yield

7.72%

TTM Avg

5.41%

3Y Avg

5.10%

5Y Avg

3.84%

BDSX

Biodesix, Inc.

vs CAMP

Market Cap

$240.50M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IVVD

Invivyd, Inc.

vs CAMP

Market Cap

$249.41M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GALT

Galectin Therapeutics Inc.

vs CAMP

Market Cap

$239.06M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AKBA

Akebia Therapeutics, Inc.

vs CAMP

Market Cap

$236.90M

EBITDA Yield

N/A

TTM Avg

6.75%

3Y Avg

3.64%

5Y Avg

3.64%

BIOA

BioAge Labs Inc.

vs CAMP

Market Cap

$234.93M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
CAMP4 Therapeutics Corporation (CAMP)	$244.74M	N/A	N/A	N/A	N/A
Lifecore Biomedical, Inc. (LFCR)vs ›	$243.81M	N/A	3.52%	3.58%	4.02%
Greenwich LifeSciences, Inc. (GLSI)vs ›	$243.66M	N/A	N/A	N/A	N/A
InflaRx N.V. (IFRX)vs ›	$241.56M	N/A	N/A	N/A	N/A
High Tide Inc. (HITI)vs ›	$240.76M	7.72%	5.41%	5.10%	3.84%
Biodesix, Inc. (BDSX)vs ›	$240.50M	N/A	N/A	N/A	N/A
Invivyd, Inc. (IVVD)vs ›	$249.41M	N/A	N/A	N/A	N/A
Galectin Therapeutics Inc. (GALT)vs ›	$239.06M	N/A	N/A	N/A	N/A
Akebia Therapeutics, Inc. (AKBA)vs ›	$236.90M	N/A	6.75%	3.64%	3.64%
BioAge Labs Inc. (BIOA)vs ›	$234.93M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

CAMP EBITDA Yield Metrics

CAMP Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics